spacer
home > pmps > spring 2007 > changing clinical trials landscape
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Changing Clinical Trials Landscape

As trials become increasingly globalised, Chris Wilson of Keats Healthcare tells PMPS how bespoke supply solutions can bring down costs

Where do you see Keats Healthcare in five years’ time?

Although the clinical trials landscape is constantly evolving to meet the challenges of both pharma and regulatory authorities, I’m confident that Keats will be at the forefront of clinical trials comparator supply. As supply chains become ever more complex and critical, Keats will continue to service the needs of the global industry by adding value to clinical trial operations. There has been a lot of talk about escalating clinical trial costs, with the cost of bringing a product to market regularly put at over $US 1 billion. Most people know that this figure is manipulated, but it should be remembered that the adjustments are made to include not only the cost of molecules that fail in the early stages of testing, but also the huge cost to the industry of trials that collapse because of poor supplies – comparator availability is a huge part of that. What is certain is that with the increased prevalence of biologics and cold chain products in trials, companies need to have confidence in their comparator supply. The industry wants full pipelines, and is rightly looking to cut trial costs and durations, but we must be careful not to cut costs in the wrong places.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After receiving an MA in Retail and Marketing from Manchester University, Chris Wilson began his career in the brewing and licensed retail industry with Carlsberg in Denmark, with roles including sales, procurement and marketing directorships. From there he was responsible for launching a leading branded wine with Pernod Ricard and spent a period as Head of Sales and Marketing at Sky TV. Chris joined Keats Healthcare Ltd as Managing Director, with a focus on providing clients with flexible and efficient clinical trial comparator supply solutions.
spacer
Chris Wilson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement